NORTH AMERICAN BUSINESS
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
NORTH AMERICAN BUSINESS
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
NORTH AMERICAN BUSINESS
No Result
View All Result
Home ALL Healthcare

Johnson & Johnson Reports Q4 and Full-Year 2022 Results

by Ed Johnson
January 25, 2023
A A

2022 Fourth-Quarter reported sales decline of 4.4% to $23.7 Billion primarily driven by unfavorable foreign exchange and reduced COVID-19 Vaccine sales vs. prior year. Operational growth excluding COVID-19 Vaccine of 4.6%*

2022 Fourth-Quarter earnings per share (EPS) of $1.33 decreasing 24.9% and adjusted EPS of $2.35 increasing by 10.3%*

2022 Full-Year reported sales growth of 1.3% to $94.9 Billion primarily driven by strong commercial execution partially offset by unfavorable foreign exchange. Operational growth of 6.1%*

2022 Full-Year earnings per share (EPS) of $6.73 decreasing 13.8% and adjusted EPS of $10.15 increasing by 3.6%*

Company guides 2023 adjusted operational sales growth excluding COVID-19 Vaccine of 4.0%* and adjusted operational EPS of $10.50, reflecting growth of 3.5%*

NEW BRUNSWICK, N.J. – Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2022. “Our full year 2022 results reflect the continued strength and stability of our three business segments, despite macroeconomic challenges,” said Joaquin Duato, Chairman of the Board and Chief Executive Officer. “I am inspired by our employees who make a difference in the health and lives of people around the world every day. As we look ahead to 2023, Johnson & Johnson is well-positioned to drive near-term growth, while also investing strategically to deliver long-term value.”

OVERALL FINANCIAL RESULTS

Q4Full Year
($ in Millions, except EPS)20222021% Change20222021%  Change
Reported Sales$23,706$24,804(4.4)%$94,943$93,7751.3%
Net Earnings$3,520$4,736(25.7)%$17,941$20,878(14.1)%
EPS (diluted)$1.33$1.77(24.9)%$6.73$7.81(13.8)%
       
Q4Full Year
Non-GAAP* ($ in Millions, except EPS)20222021%  Change20222021%  Change
Operational Sales1,20.9%6.1%
Adjusted Operational Sales1,30.8%6.2%
Adjusted Net Earnings1,4$6,218$5,6789.5%$27,038$26,1953.2%
Adjusted EPS (diluted)1,4$2.35$2.1310.3%$10.15$9.803.6%

 1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules

  2 Excludes the impact of translational currency

  3 Excludes the net impact of acquisitions and divestitures and translational currency

  4 Excludes intangible amortization expense and special items

Note: values may have been rounded

REGIONAL SALES RESULTS

Q4% Change
($ in Millions)20222021ReportedOperational1,2CurrencyAdjusted Operational1,3
U.S.$12,516$12,1632.9%2.9–2.7
International11,19012,641(11.5) (1.1)(10.4)(1.0)
Worldwide$23,706$24,804(4.4)%0.9(5.3)0.8
Full Year% Change
($ in Millions)20222021ReportedOperational1,2CurrencyAdjusted Operational1,3
U.S.$48,580$47,1563.0%3.0–3.0
International46,36346,619(0.6)%9.1(9.7)9.3
Worldwide$94,943$93,7751.3%6.1(4.8)6.2

 1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules

 2 Excludes the impact of translational currency

 3 Excludes the net impact of acquisitions and divestitures and translational currency

Note: Values may have been rounded

SEGMENT SALES RESULTS

Q4% Change 
($ in Millions)20222021ReportedOperational1,2CurrencyAdjusted Operational1,3 
Consumer Health4$3,767$3,7281.0%6.4(5.4)6.4
Pharmaceutical413,16314,217(7.4) (2.5)(4.9)(2.3)
MedTech6,7766,859(1.2) 4.9(6.1)4.4
Worldwide$23,706$24,804(4.4)%0.9(5.3)0.8
Full Year% Change
($ in Millions)20222021ReportedOperational1,2CurrencyAdjusted Operational1,3
Consumer Health4$14,953$15,035(0.5)%3.6(4.1)3.9
Pharmaceutical452,56351,6801.7  6.7(5.0)6.8
MedTech27,42727,0601.4  6.2(4.8)6.1
Worldwide$94,943$93,7751.3%6.1(4.8)6.2

  1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules

  2 Excludes the impact of translational currency

  3 Excludes the net impact of acquisitions and divestitures and translational currency

  4 Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes

Note: Values may have been rounded

Tags: < Financial Results
ShareTweetShareSend

Related Industries

Healthcare

Bristol Myers Squibb Announces Progress Toward Long-Term Inclusion & Diversity Goals and Health Equity Commitments

March 16, 2023
Healthcare

Medtronic named one of World’s Most Ethical Companies

March 14, 2023
Healthcare

Pfizer Invests $43 Billion to Battle Cancer

March 14, 2023
Healthcare

AskBio Announces Gustavo Pesquin as New CEO

March 10, 2023
Healthcare

Johnson & Johnson Announces Pricing of $7.75 Billion of Senior Notes Issued by Kenvue Inc.

March 9, 2023
Healthcare

Interview with Dr. Erik Walker, Board Chairman, Orlando Health Network

March 6, 2023

Hudson County Engages Honeywell To Help Develop And Implement A Smart Community Program

March 3, 2023

...

Siemens Mobility to invest $220 million into North Carolina rail manufacturing facility

March 8, 2023

...

Celanese and Mitsui & Co., Ltd. to Form Food Ingredients Joint Venture; Extend Existing Fairway Methanol LLC Joint Venture

February 24, 2023

...

chevron and JERA sign MOU to explore carbon capture and storage projects in United States and Australia

March 8, 2023

...

The Estée Lauder Companies Appoints Lahnie Strange to Senior Vice President, Global General Manager, Bobbi Brown Cosmetics

March 4, 2023

...

CVC wins five awards at the Private Equity International and Private Debt Investors Awards 2022

March 2, 2023

...

Marriott International Receives Regulatory Approval To Complete City Express Brand Acquisition

March 11, 2023

...

AbbVie and Capsida Biotherapeutics Expand Strategic Collaboration to Develop Targeted Genetic Medicines for Eye Diseases with High Unmet Need

February 24, 2023

...

Aramco completes $2.65bn acquisition of Valvoline Inc’s global products business (‘Valvoline Global Operations’)

March 3, 2023

...

NORTH AMERICAN BUSINESS (www.na-biz.com) is a leading source of business and corporate news, information, industry trends, market updates and insights across a broad spectrum of industries in North America and worldwide.

INDUSTRIES

  • Aero
  • Agriculture
  • ALL
  • Automotive
  • Business Service
  • Chemical
  • Construction
  • Construction Materials
  • Consumer
  • Education
  • Energy
  • Entertainment
  • Environmental
  • F&B
  • Financial
  • Healthcare
  • Hospitality
  • Industrial
  • IT
  • IT Hardware
  • Logistic
  • Metal & Mining
  • Packaging & Paper
  • Rail
  • Real Estate
  • Telecom

CONTACT US

EDITORIAL:     editor#na-biz.com

PARTNERSHIP:     biz#na-biz.com

HUMAN RESOURCE:     hr#na-biz.com

* (replace # with @)

  • Official Site

Copyright © NA-BIZ.COM All rights reserved.

No Result
View All Result
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

Copyright © NA-BIZ.COM All rights reserved.